Overview

BMS-741672 for Diabetic Neuropathic Pain

Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of the study is to determine whether BMS-741672 improves neuropathic pain in diabetic patients.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Bristol-Myers Squibb
Criteria
Inclusion Criteria:

- Type 1 or 2 diabetics with painful, distal, symmetrical, sensory-motor neuropathy
attributed to diabetes, of at least 12 months duration

- Screening HbA1c of ≥ 7% and ≤ 10%

- BMI ≤ 40 kg/m2

Exclusion Criteria:

- Patients with clinically significant, progressive, or potentially unstable disease of
any body system including cardiovascular, gastrointestinal, central nervous system
(CNS), psychiatric, endocrine (other than diabetes), tuberculosis or renal

- Women of childbearing potential